{"product_id":"biolegend-400157","title":"Biolegend, 400157, Brilliant Violet 421™ Mouse IgG1, κ Isotype Ctrl Antibody, 25tests","description":"\u003cp\u003eThe MOPC-21 immunoglobulin has unknown specificity. The isotype of this antibody is mouse IgG1, κ. This antibody was chosen as an isotype control after screening on a variety of resting, activated, live, and fixed mouse, rat and human tissues.\u003cbr\u003e\n25tests\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Mouse\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).\u003cbr\u003e\nPreparation: The immunoglobulin was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.\u003cbr\u003e\nConcentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this mouse IgG1, κ isotype control antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, use the isotype control at the same concentration as your primary antibody. Use our Concentration Lookup tool to find the exact concentrations of your lots of product. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450\/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.\u003cbr\u003e\nExcitation Laser: Violet Laser (405 nm)\u003cbr\u003e\nApplication Notes: Additional reported applications (for the relevant formats) include: Intracellular Flow Cytometry (ICFC), Immunocytochemistry (ICC), Immunohistochemistry (IHC), Immunoprecipitation (IP), Western Blotting (WB), Functional Assay (FA)\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Carlsten M, et al. 2007. Cancer Res. 67:1317. PubMed Smed-Sörensen A, et al. 2008. Blood 111:5037. PubMed (FA) Bunesmann MM, et al. 2011. Am. J. Respir. Cell. Mol. Biol. Epub. PubMed Matsuyama T, et al. 2005. Infect. Immun. 73:1044. (IF) Correia DV, et al. 2011. Blood 118:992. (FC) PubMed Lian IA, et al. 2011. Placenta. 32:823. PubMed Bufe B, et al. 20015. J Biol Chem. 290:7369. PubMed\u003cbr\u003e\nProduct Citations: Gravina A, et al. 2023. Nat Biotechnol. 41:717. PubMed Campbell KA, et al. 2023. Commun Biol. 6:264. PubMed Lee HS, et al. 2023. Biol Pharm Bull. 46:542. PubMed Imai H, et al. 2023. iScience. 26:106822. PubMed Bhatt RS, et al. 2021. Cancer Immunol Res. 9:156. PubMed Kemble S, et al. 2022. Blood Adv. 6:2932. PubMed Iancu O, et al. 2023. Mol Ther Nucleic Acids. 31:105. PubMed Uneda A, et al. 2021. Acta Neuropathol Commun. 9:29. PubMed Bratti M, et al. 2022. Front Immunol. 13:1029759. PubMed Girard MC, et al. 2021. Sci Rep. 11:5511. PubMed Hinterbrandner M, et al. 2021. JCI Insight. 6:e151797. PubMed Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed Eremichev R, et al. 2021. Front Cell Dev Biol. 616893:9. PubMed Kobayashi Y, et al. 2020. Int J Oncol. 999:56. PubMed Herter JM, et al. 2022. Strahlenther Onkol. Online ahead of print. PubMed Eriksson E, et al. 2019. J Immunol. 202:787. PubMed Ehlers L, et al. 2021. The FASEB Journal. 35(7):e21684. PubMed Cornelius C et al. 2016. EBioMedicine. 11:58-67 . PubMed Jürchott K, et al. 2016. PLoS One. 11: 0150812. PubMed Nur Patria Y, et al. 2020. Stem Cell Research. 72.79305556. PubMed Luo Y, et al. 2021. Nat Commun. 12:3913. PubMed Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed Eikmans M, et al. 2022. Front Immunol. 13:814019. PubMed Dayang EZ, et al. 2021. Biomed Pharmacother. 133:111073. PubMed Grant R, et al. 2021. Methods Protoc. 4:. PubMed Dayang EZ, et al. 2019. Front Immunol. 10:1169. PubMed Wang S, et al. 2021. Parasite. 28:13. PubMed van Stigt Thans T, et al. 2020. Journal of Virology. 93(20):e00719-19.. PubMed Wu M, et al. 2020. Mucosal Immunol. 13:47. PubMed Tamai K, et al. 2022. Cell Rep Methods. 2:100314. PubMed Kim Y, et al. 2021. Oncol Lett. 1.022222222. PubMed Farhat AM, et al. 2021. Cell Reports. 35(4):109044. PubMed Blackburn M, et al. 2015. J Immunol. 195: 3227 - 3236. PubMed Sharma VP, et al. 2021. Nat Commun. 12:7300. PubMed\u003cbr\u003e\nRRID: AB_10897939 (BioLegend Cat. No. 400157) AB_11150232 (BioLegend Cat. No. 400158)\u003cbr\u003e\nGene ID: NA\u003cbr\u003e\nClone: MOPC-21\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nIsotype: Mouse IgG1, κ\u003cbr\u003e\nQ: What is the F\/P ratio range of our BV421™ format antibody reagents?\u003cbr\u003e\nA: It is lot-specific. On average it ranges between 2-4.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46866144723113,"sku":"400157","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/biolegend-400157","provider":"Iright","version":"1.0","type":"link"}